H.C. Wainwright analyst Robert Burns raised the firm’s price target on Y-mAbs Therapeutics to $22 from $21 and keeps a Buy rating on the shares post the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics reports Q1 EPS (15c), consensus (14c)
- Y-mAbs Therapeutics Board Member Dr. Ber Announces Resignation
- Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
- Y-mAbs to Present at 2024 ASCO Annual Meeting
- Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition